News, Short Squeeze, Breakout and More Instantly...
Hansa Biopharma AB Company Name:
HNSBF Stock Symbol:
OTCMKTS Market:
Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation PR Newswire Statistically significant reduction in donor-specific antibodies (DSAs) observed among imlifidase patients within five days of treatment as compared ...
Hansa Biopharma interim report January-March 2023 PR Newswire Positive reimbursement decision in Spain expands market access to include the five largest European markets Enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS) completed HNSA-...
The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma's Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients PR Newswire Idefirix ® becomes the first and only product recommended by SMC...